CCL5 Composition for Skeletal Stem Cell Recruitment in Bone Repair

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods lack the ability to specifically recruit skeletal stem cells (SSCs) to a specific site for bone repair, as there is a lack of specific markers to distinguish SSCs at different locations and the cellular complexity of injury models generated through disruption of the bone compartment's physical barrier, making the direct effect of cytokines on endogenous SSCs during injury healing unclear.

Innovation Solution

A composition comprising CCL5 is administered to a specific site in need, such as a bone break, fracture, or osteoporosis, to recruit periosteal skeletal stem cells (P-SSCs) and induce bone healing, which can be delivered with a biocompatible gel or scaffold, and may include additional therapies like surgical repair or fixation devices.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If multiple cytokines and growth factors are used to enhance skeletal repair, then bone healing is promoted, but the direct effect on endogenous SSCs remains unclear due to cellular complexity and lack of specific markers

Engineering Contradiction:
Improvebone healing effectivenessVSAvoidcellular complexity of injury models
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses specific SSC markers (Nestin, CD105, CD140a) as intermediaries to identify and track skeletal stem cells during fracture repair. This allows researchers to distinguish SSCs from other cell types in the complex injury environment, thereby clarifying the direct effects of cytokines like CCL5 on these specific cells while maintaining the overall complexity of the bone healing process

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the parameter of cell identification from general morphological characteristics to specific molecular markers (Nestin, CD105, CD140a expression patterns). This parameter change enables precise tracking of SSCs within the complex cellular environment of fracture sites, allowing clear observation of cytokine effects on these specific cells

Inventive Principle:
Principle #35Parameter changes

2Productivity

If SSCs are recruited to specific sites for bone repair, then fracture healing is enhanced, but the ability to specifically recruit SSCs to a specific site is currently lacking

Engineering Contradiction:
Improvebone repair efficiencyVSAvoidspecificity of SSC recruitment
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The patent employs CCL5 cytokine administration that creates a feedback mechanism: CCL5 binds to CCR5 receptors on SSCs, triggering chemotactic migration toward the fracture site. This feedback loop ensures SSCs are specifically recruited to where they are needed (fracture sites with CCL5 expression) rather than being distributed randomly, thereby enhancing repair efficiency with precise spatial targeting

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent uses CCL5-CCR5 interaction as an intermediary mechanism to achieve specific SSC recruitment. The CCL5 cytokine acts as a chemical signal that mediates the attraction of SSCs expressing CCR5 receptors to the fracture site, providing the specificity that was previously lacking in bone repair approaches

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of CCL5 effectively recruits P-SSCs to differentiate into osteoblasts, aiding in bone healing and reducing osteoclast migration, thereby enhancing bone repair and regeneration.

Implementation Method 1

The administration of CCL5 effectively recruits P-SSCs to differentiate into osteoblasts

Methodology Applied
Scientific EffectChemotaxis:

Data Source

PatentEP3921029B1Composition comprising CCL5 for use in treating bone break, bone fracture, bone degeneration and osteoporosis
Publication Date: 2025.07.30 BAYLOR COLLEGE OF MEDICINE
  • EP3921029B1 patent drawingFigure 1A
  • EP3921029B1 patent drawingFigure 1B
  • EP3921029B1 patent drawingFigure 1C

AI summary

Embodiments of the disclosure encompass methods and compositions for bone repair and bone injury healing. In some embodiments, the bone repair and bone injury healing utilizes the enhancement of migration of certain types of bone cells upon stimulation by a particular cytokine. In specific embodiments, migration of periosteal skeletal stem cells upon delivery of CCL5 and/or TNFα is enhanced and fosters bone repair and healing.